TFA
NBIX icon

Toth Financial Advisory’s Neurocrine Biosciences NBIX Stock Holding History

Toth Financial Advisory’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-5,680
Closed -$782K – 751
2024
Q2 		$782K Buy
5,680
+180
+3% +$24.7K 0.1% 132
2024
Q1 		$759K Buy
5,500
+1,413
+35% +$193K 0.09% 139
2023
Q4 		$539K Buy
+4,087
New +$470K 0.07% 162
2023
Q1 		– Sell
-7,185
Closed -$858K – 839
2022
Q4 		$858K Buy
+7,185
New +$842K 0.14% 113
2020
Q4 		– Sell
-490
Closed -$47K – 616
2020
Q3 		$47K Sell
490
-6,845
-93% -$792K 0.01% 245
2020
Q2 		$895K Buy
7,335
+6,130
+509% +$677K 0.19% 98
2020
Q1 		$104K Sell
1,205
-4,350
-78% -$426K 0.03% 142
2019
Q4 		$597K Buy
+5,555
New +$582K 0.12% 115

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Toth Financial Advisory's NBIX Position: Q3 2024 in Review

Toth Financial Advisory sold out of Neurocrine Biosciences (NBIX) in Q3 2024, closing a stake of 5,680 shares — an estimated $782K sold.

Toth Financial Advisory first reported a position in NBIX in Q4 2019 and held it in 8 quarters. The position peaked at $895K in Q2 2020. 574 funds tracked by Wall St. Rank hold NBIX as of Q3 2024.

  • Toth Financial Advisory reported no remaining Neurocrine Biosciences position as of Q3 2024 after selling out during the quarter.
  • Toth Financial Advisory sold 5,680 Neurocrine Biosciences shares in Q3 2024, an estimated $782K.
  • Toth Financial Advisory first reported a position in Neurocrine Biosciences in Q4 2019 and held it in 8 quarters.
  • Toth Financial Advisory's Neurocrine Biosciences position peaked at $895K in Q2 2020.
  • 574 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2024.

Based on Toth Financial Advisory's 13F filing for Q3 2024, filed 21 Oct 2024.